Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic

Checkpoint inhibitors and T-cell therapies have highlighted the critical role of T cells in anti-cancer immunity. However, limitations associated with these treatments drive the need for alternative approaches. Here, we engineer red blood cells into artificial antigen-presenting cells (aAPCs) presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuqing, Luo, Mengyao, Dastagir, Shamael R., Nixon, Mellissa, Khamhoung, Annie, Schmidt, Andrea, Lee, Albert, Subbiah, Naren, McLaughlin, Douglas C., Moore, Christopher L., Gribble, Mary, Bayhi, Nicholas, Amin, Viral, Pepi, Ryan, Pawar, Sneha, Lyford, Timothy J., Soman, Vikram, Mellen, Jennifer, Carpenter, Christopher L., Turka, Laurence A., Wickham, Thomas J., Chen, Tiffany F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113241/
https://www.ncbi.nlm.nih.gov/pubmed/33976146
http://dx.doi.org/10.1038/s41467-021-22898-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113241/
https://www.ncbi.nlm.nih.gov/pubmed/33976146
http://dx.doi.org/10.1038/s41467-021-22898-3

Ejemplares similares